Regulatory Rapporteur June 2012

<< back to list of Issues

Front Cover
Volume 9 Issue 6

In This Issue

  • Focus - Benefit–risk
  • PLUS
  • Nonclinical aspects of biosimilar development – A regulatory perspective
  • Changes to EN 60601-1 and how to maintain MDD compliance
  • Nutraceuticals and functional food regulations in key emerging markets: Part 2 – Specifics

Please login to view member only articles. Non-members may download the public articles.

Regulatory Rapporteur June 2012MembersFull Issue4MBPDF
Evaluating benefit-risk: An Agency PerspectivePublic2MBPDF
Evaluating benefit–risk during and beyond drug development: An Industry ViewPublic915KBPDF